1. Introduction {#s0005}
===============

The leishmaniases are a group of infections caused by parasites of the genus *Leishmania*, which are transmitted through the bite of female phlebotomine sand flies, through either a zoonotic or anthroponotic cycle ([@bb0065]). Most dermal leishmaniasis cases are localized cutaneous leishmaniasis (CL) but other more aggressive forms include, diffuse cutaneous leishmaniasis (DCL), mucosal leishmaniasis (ML) and cutaneous leishmaniasis recidivans (CLR), which in total account for an estimated 0.7--1.2 million cases/year worldwide ([@bb0015]). Another form of dermal leishmaniasis is post-kala azar dermal leishmaniasis (PKDL), a complication of visceral leishmaniasis (VL) caused by *Leishmania donovani* that affects up to 5% of VL cases in the Indian subcontinent and up to 50% in eastern Africa. PKDL patients may also play an important role in transmission of *L. donovani* ([@bb0070]; [@bb0080]). Although not lethal, dermal leishmaniases cause chronic and disfiguring skin lesions, which are an important cause of morbidity and social stigma ([@bb0050]; [@bb0035]; [@bb0040]; [@bb0055]; [@bb0045]).

Microscopy of Giemsa stained samples from lesions, including skin scrapings, fine needle aspirates, or slit-skin smears, remains the reference test for diagnosis of the different forms of dermal leishmaniasis. However, microscopy has a low and variable sensitivity and requires trained and experienced personnel ([@bb0025]; [@bb0005]). As a result a high number of patients are put on treatment without laboratory confirmation, exposing a variable number of them to unnecessary toxic treatment ([@bb0080]; [@bb0075]). The technical complexity and cost of the more sensitive molecular techniques (e.g. PCR) limits their application as routine diagnostic tools in endemic areas. Other simpler tests for detection of leishmanial DNA, such as loop-mediated isothermal amplification (LAMP), are yet to be implemented ([@bb0025]; [@bb0010]; [@bb0060]). Other approaches include serology, which may be useful for screening of PKDL and mucosal leishmaniasis, but cannot be used for confirmation as presence of antibodies may be due to previous episodes or exposure to the parasite by living in endemic areas. The leishmanin skin test (LST) can also aid in the diagnosis of CL, but again the tests is not a marker of active infection, and therefore has limited value ([@bb0065]; [@bb0080]; [@bb0025]).

Thus there is a great need for point-of-care (POC) tests for early diagnosis of dermal leishmaniases, in order to benefit both patients and communities by early identification of those that need treatment, reducing the risk of both sequelae and ongoing *Leishmania* transmission. It is then important that new POC tests to be developed meet the needs of the target population and the requirements for implementation in resource-limited settings, where most cases of dermal leishmaniasis occur. To this end we present here a Target Product Profile (TPP) for a POC test for dermal leishmaniases that was defined through consensus with stakeholders and experts in these forms of leishmaniases.

2. Methods {#s0010}
==========

Target Product Profiles (TPPs) for diagnostics provide details on the desired minimal and optimal features of priority diagnostic tests, including performance and operational characteristics. Adherence to TPPs ensures that research and development activities are focused on products designed for the contexts and needs of end users. To develop a TPP for a POC for dermal leishmaniases we followed a three steps process: i) a draft TPP was developed by the leishmaniasis groups at the Foundation for Innovative New Diagnostics (FIND) and Drug for Neglected Diseases initiative (DNDi), ii) the draft TPP was discussed at a meeting of experts in leishmaniasis, and a revised version was prepared, then iii) the revised version was reviewed through an online survey with a larger audience of stakeholders and experts, and a consensus TPP developed.

The draft TPP had 29 test features for which optimal (desired) and minimally accepted targets were defined. This first draft was presented at the 2nd redeLEISH Meeting (Medellín, Colombia, July 2015) for discussion with a panel of 70 experts on leishmaniasis ([@bb0030]). The draft was refined based on the inputs received from experts in that meeting, and a new document prepared to be shared with a second panel of experts. Eighty-two experts in leishmaniasis and stakeholders were invited to participate in an online review of the TPP. Participants were requested to indicate their level of agreement with the optimal and minimal targets proposed for each feature, using a scale from 1 to 5, where 1 = Disagree, 2 = Somewhat disagree, 3 = Neither agree or disagree, 4 = Mostly agree and 5 = Fully agree. Where the level of agreement was 3 or less, the experts were requested to provide an explanation. The consensus among experts was scored as the percentage that indicated a level of agreement of \>4 (mostly agree or 5, fully agree).

3. Results {#s0015}
==========

Out of 82 experts invited to participate in the online review, 31 completed the full questionnaire indicating their level of agreement with each of the features in the TPP. The experts were drawn from different endemic regions and types of organizations ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Distribution of people who participated in an online review of the TPP for dermal leishmaniases according to WHO region (A) and type of organization (B).Fig. 1

There was consensus on all features (i.e. \>50% of replies were either "mostly agree" or "fully agree"). The consensus scores were high for both the optimal (mean % of replies scoring 4 or 5 = 92.5 ± 9.3) and minimal targets (88.5 ± 11.1). Details on the features of TPP defined and the consensus scores for each of them is given in [Table 1](#t0005){ref-type="table"}.Table 1Target Product Profile for a point-of-care diagnostic test for dermal leishmaniases.Table 1FeatureOptimalMinimalRationale and evidenceConsensus scorePriority features: SCOPE1. Goal of test. Intended useDetection of active CL (any form) or PKDL with the purpose of initiating treatment during the same clinical encounter (or same day)Detection of active LCL.LCL is the most prevalent form of dermal leishmaniasis (\>80% of the cases). This clinical form is present in all CL endemic regions. All *Leishmania* species cause LCL. Other forms of CL usually evolve from LCLOptimal 100%\
Minimal 97%2. Target populationIndividuals with clinical signs suggestive of any form of CL, or PKDLIndividuals with clinical signs suggestive of LCLOptimal 100%\
Minimal 97%3. Target operator of testHealth worker at PHC level without laboratory trainingTrained laboratory staffMost patients go to health facilities with limited human resourcesOptimal 90%\
Minimal 93%4. Lowest setting for implementation.\
Target use settingDecentralized health care facilities with no laboratory infrastructure, or mobile teamDecentralized health care facilities with minimum laboratory infrastructureThis test could replace microscopy, as has happened with other diseases (e.g. malaria)Optimal 93%\
Minimal 90%5. Target analyte to be detected*Leishmania* antigenOptimal 84%\
Minimal 87%  Priority features: PERFORMANCE CHARACTERISTICS6. Clinical sensitivity100% in parasitologically confirmed cases95% in parasitologically confirmed casesMeasured in frozen or fresh samples from parasitologically confirmed patients (microscopy and/or culture and/or PCR from skin scrapings, swabs, biopsies, aspirates, etc.). A combined reference standard according to each region should be consideredOptimal 90%\
Minimal 90%7. Clinical specificity\>95%\>90%Tested against reference standard (according to each endemic setting), including subjects with other diseases affecting the skinOptimal 90%\
Minimal 81%8. *Leishmania* species-specificity*Leishmania* species-specific*Leishmania* genus-specificDifferent treatment options might be needed for different speciesOptimal 90%\
Minimal 90%9. Type of analysis. QuantitationQualitativeThere is no need for quantification as parasite burden will not guide therapyOptimal 97%\
Minimal 97%  Priority features: TEST PROCEDURE10. Training needs. Time dedicated to training session for end usersLess than half a day for any level health care worker. Job aid providedOne day for any level health care worker. Job aid providedOptimal 100%\
Minimal 100%11. Sample typeLesion swabLesion fine needle aspirate, skin scrapping, biopsy, etc.Minimally invasive sampling procedures will be preferredOptimal 87%\
Minimal 80%12. Sample preparation. Total stepsDirect testing from lesion swab3--5 simple steps procedureOptimal 90%\
Minimal 90%13. Number of steps to be performed by operator\<3; 1 timed steps\<10; 1 timed stepsOptimal 100%\
Minimal 64%14. Need for operator to transfer a precise volume of sampleNoAcceptable with a disposable transfer device providedSample may need to be eluted in specific buffer (included in the kit)Optimal 90%\
Minimal 93%15. Time to result\<20 min\<1 hOptimal 93%\
Minimal 90%16. Internal controlIncludedPositive control to confirm validity of the testOptimal 97%\
Minimal 97%17. Reading system\
How the test result will be seenVisual (naked eye).Visual (naked eye) or simple reading deviceOptimal 97%\
Minimal 93%18. Auxiliary equipmentNone, instrument free (required materials are included in the kit)Test reader (for lateral flow assay, dual path platform, or similar)Connectivity: the reader could enable sending results to a reference lab, coordinatorOptimal 100%\
Minimal 84%19. Power RequirementsNone requiredSmall, portable or hand-held instrument (\<1 kg) that can operate on rechargeable battery or solar power lasting at least 4 h (8 h preferred)Optimal 93%\
Minimal 87%20. Need for maintenance/spare partsNoneOptimal 97%\
Minimal 97%  Priority features: OPERATIONAL CHARACTERISTICS21. Operating conditions5--50 °C, up to 90% relative humidity (RH), 0--4000 m above sea level5--40 °C, up to 80% RH, 0--2000 m above sea levelHigh environmental temperatures and high humidity are often a problem in countries where CL is endemic. Some laboratories for CL diagnosis are located at high altitude (e.g. La Paz, Bolivia)Optimal 97%\
Minimal 93%22. Reagent kit transportNo cold chain required; tolerance of transport stress for a minimum of 72 h at −15 °C to 50 °CNo cold chain required; tolerance of transport stress for a minimum of 48 h at −15 °C to 50 °CRefrigerated transport is costly and often cannot be guaranteed during the entire transportation process. Frequent delays in transport are commonOptimal 93%\
Minimal 97%23. Reagent kit storage/stabilityNo cold chain required. Up to 24 months at 50 °C, up to 90% humidityNo cold chain required. Up to 12 months at 40 °C, up to 70% humidityShould be able to tolerate transport stress (48 h at 50 °C). To include test quality detector (for surpassed T or RH)Optimal 93%\
Minimal 93%24. Reagents reconstitution. Need to prepare the reagents prior to utilizationAll reagents ready to useOptimal 97%\
Minimal 97%25. In use stability\>1 h for single use test after opening the pouchHigh environmental temperatures and high humidity are often a problem in countries where CL is endemicOptimal 100%\
Minimal 97%26. Biosafety requirement. Level of protection to be made.\
Available for the staff and the samplesNo need for biosafety cabinet. Standard biosafety precautions when handling potentially infectious materials. No contraindications to routine useOptimal 100%\
Minimal 100%  Priority features: PRICING27. Maximum price for individual test.\<1 USD per test\<5 USD per testAssumption that the test is produced at a large scale, transport costs from producing company not included.Optimal 97%\
Minimal 68%28. Maximum price for instrumentation. If needed\<2000 USD\<2000 USDIn case a test reading device is needed.Optimal 55%\
Minimal 58%29. Expected scale of manufacture2.5 million test per year1.0 million test per yearBased on 0.7--1.2 million estimated CL cases; and provided the test has better performance than microscopyOptimal 74%\
Minimal 68%[^2]

4. Discussion {#s0020}
=============

Due to the low sensitivity and/or specificity, as well as the complexity of some of the techniques currently available for CL diagnosis, most patients do not have access to early and reliable diagnosis, which increases morbidity and decreases the possibility of control. To advance CL control, new diagnostic options that are affordable, simple, specific, sensitive, and robust are still needed, preferably in the format of a rapid diagnostic test.

Stakeholders and experts in leishmaniasis participated in the development of the TPP described here, which can be used to guide product development. The aim should be for a rapid (\<1 h), simple (\<10 steps) and robust (stable at defined temperature and humidity) test that can be implemented in resource-limited settings enabling decentralized management of dermal leishmaniases. Ideally the test can be used to diagnose all forms of dermal leishmaniases, including CL and its complicated forms as well as PKDL. The minimally accepted target would be localized CL, the most prevalent, and the one that if diagnosed early, would reduce the risk of developing other forms such as mucosal leishmaniasis and cutaneous leishmaniasis recidivans. The targeted sensitivity should be at least 95% in parasitologically confirmed patients. Specificity should reach a minimum of 90%, to avoid treating non-leishmaniasis patients with other dermal conditions.

The experts who participated in the process of developing the TPP described here agreed that the POC test should target *Leishmania* antigens. Optimally, the test should be able to identify *Leishmania* species, as this enable the adaptation of treatment according to the infecting species. However, a test with broad specificity for the whole *Leishmania* genus would be a minimally accepted target, a test able to detect an antigen that is common across species and that can be used with different sample types may present additional advantages: (i) it can be used to diagnose CL caused by species of both the *Leishmania* and *Viannia* subgenera, (ii) it can be used as well to diagnose other clinical forms evolving from CL such as ML, CLR and DCL; and (iii) by detecting species of the *L. donovani* complex, the diagnosis of PKDL and VL (if the test can also be used in urine or blood) would be possible.

An important aspect to take into consideration during test development would be its affordability. Features related to the test price were the most discussed by experts, and for these lower consensus scores were obtained (see [Table 1](#t0005){ref-type="table"}, features 27--29). Dermal leishmaniases mainly affect poor populations in low and middle income countries that have limited resources to address public health issues. As a consequence, the resources devoted to improving their management and control are scarce. However interventions that allow early detection and treatment would contribute to reducing a huge burden of disease, which is often overlooked, and indirectly, poverty ([@bb0020]). The TPP of a POC diagnostic test for dermal leishmaniases described here could be an important guide in the development of such a test.
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